| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha.
Correspondence to Irving H. Zucker, PhD, Department of Cellular and Integrative Physiology, 985850 Nebraska Medical Center, Omaha, NE 68198-5850. E-mail izucker{at}unmc.edu
| Abstract |
|---|
|
|
|---|
Key Words: free radicals angiotensin receptors RVLM ventricular pacing
| Introduction |
|---|
|
|
|---|
A growing body of evidence now indicates NAD(P)H oxidase-derived reactive oxygen species (ROS) as important mediators of Ang II signaling.5 Ang II not only augments ROS formation and increases the oxidase activity, but it also upregulates mRNA and protein expression of most NAD(P)H oxidase subunits in vitro6 and in vivo.7 The degree of oxidative stress and ROS is determined by the balance between ROS generation and oxidant scavenging. Several studies have documented reductions in superoxide dismutation in peripheral tissues in the CHF state.8,9 Unfortunately, there has been a lack of studies that focus on the central nervous system in this regard. Interestingly, in a recent study by Lindley et al,10 it was clearly shown that central transfection with an adenovirus coding for Cu/Zn superoxide dismutase (SOD) reduced sympathoexcitation in mice with chronic myocardial infarctions. Considering that ROS play an important role in the development and progression of heart failure,11 we hypothesized that central Ang II via an AT1 receptor mechanism activates sympathetic outflow by stimulation of NAD(P)H oxidase and ROS in the CHF state. Therefore, the present study was performed, in conscious sham and CHF rabbits, to: (1) determine the effects of altered levels of central ROS using intracerebroventricular infusions of the SOD mimetic tempol, the inhibitor of NAD(P)H oxidase apocynin, and the inhibitor of SOD, diethyldithio-carbamic acid (DETC), on resting or Ang II-induced sympathetic nerve activity; and (2) evaluate mRNA and protein expression of the AT1 receptor and NAD(P)H oxidase subunits as well as the superoxide anion (O2) in the rostral ventrolateral medulla (RVLM), a major site of sympathoexcitation in response to Ang II administered into the cerebrospinal fluid.12
| Materials and Methods |
|---|
|
|
|---|
Induction of CHF
Rabbits underwent sterile thoracic instrumentation and then were paced to induce CHF, as described previously.13 Details of instrumentation and echocardiographic analysis are available in the online data supplement at http://circres.ahajournals.org.
Arterial Pressure and Heart Rate Recording
A catheter connected to a radio telemetry unit (Data Sciences International) was inserted into the descending aorta via a branch of the right femoral artery for direct measurement of arterial pressure (AP) in the conscious state. Heart rate (HR) was derived from the AP pulse using a PowerLab (Model 8S; AD Instruments Inc.) data acquisition system.
Brain Guide Cannula Implantation
The skull was exposed through an incision on the midline of the scalp. After the bregma was identified, a 19-gauge stainless-steel guide cannula was implanted into the right lateral cerebral ventricle 4 mm lateral to the bregma and 6 mm below the cerebral surface. The position of the cannula in the lateral cerebral ventricle was confirmed by the staining of all four ventricles after injection of 0.1 mL of Evans Blue dye at the end of the experiments. The cannula was fixed to the skull with dental cement and was sealed by a 21-gauge obturator.
Renal Sympathetic Nerve Recording
Renal sympathetic nerve recording electrodes were implanted as we have described previously.14 Experiments were performed 3 to 14 days after nerve electrodes were implanted (see online data supplement for details).
Measuring Superoxide Anion Production in the RVLM
Homogenates were prepared from RVLM samples. Total protein concentration was determined using a bicinchoninic acid protein assay kit (Pierce). Superoxide anion production was measured using lucigenin chemiluminescence method1517 (TD-20/20 Luminometer; Turner Designs; see online data supplement for details).
In Situ Detection of O2 Production in RVLM
Dihydroethidim (DHE), an oxidative fluorescent dye, was used to detect in situ superoxide in the RVLM of rabbits as described,18 with minor modification (see online data supplement for details).
RT-PCR Analysis of AT1 Receptor and NAD(P)H Subunit mRNA in the RVLM
Tissue punches were taken from the RVLM as described below. Total RNA of RVLM was isolated by means of the RNeasy Mini Kit Total RNA Isolation System (Qiagen), after which cDNA was synthesized by means of Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies). PCR amplification was performed by means of a PTC-100 Programmable Thermal Controller (MJ Research) as follows: 1 cycle at 95°C for 15 minutes, followed by 35 cycles of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for 1 minute. PCR products for the subunits gp91phox, p67phox, p47phox, p40phox, and p22phox were visualized on 2% agarose gels by use of ethidium bromide and sequenced so their identity could be confirmed. The bands were analyzed using UVP BioImaging Systems. Specific methodologies and gene sequences are available in the online data supplement.
Western Blot Analysis of AT1 Receptor and NAD(P)H Subunits Protein in the RVLM
The RVLM was homogenized with the homogenizer in radioimmunoprecipitation assay buffer. Protein extraction from homogenates was used for Western blot analysis for the rabbit AT1 receptor, gp91phox, p67phox, p47phox, and p40phox (see online data supplement for details).
Experimental Protocols
On the day of the experiment, the conscious rabbit was placed in a Plexiglas box in a dimly lit, quiet laboratory. After a 30-minute stabilization period, baseline renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP), and HR were recorded, and then the rabbit was treated with an intracerebroventricular infusion (30 minutes) of the following agents: Ang II (50 pM per 5 µL/min) alone, losartan (100 nM per 5 µL/min) alone, Ang II+losartan, tempol (10 µg per 5 µL/min) alone, Ang II+tempol, apocynin (8 µg per 5 µL/min) alone, Ang II+apocynin, or DETC (10 µg per 5 µL/min) in seven separate experiments one day apart.
Five days after the last experiment, the rabbit was euthanized with pentobarbital sodium. The brain was removed and immediately frozen on dry ice, blocked in the coronal plane, and sectioned at 300-µm thickness in a cryostat. The RVLM was punched according to the method of Palkovits and Brownstein19 for analysis of O2 production, mRNA, and protein of AT1 receptor and NAD(P)H subunits.
Data and Statistical Analysis
Because the effects of intracerebroventricular infusion of Ang II on MAP and RSNA usually started at
10 minutes, reached the peak in
15 minutes, and then maintained that level until the end of the infusion, data were taken usually between 20 and 30 minutes after Ang II infusion. Changes in RSNA were similar when quantified using either voltage integration or spike discharge rate. The RSNA discharge data in the present study are presented using the rate meter method. All measurements were averaged every 30 seconds.
Data are expressed as the mean±SE. The differences between groups were determined with a two-way ANOVA followed by the Newman-Keuls test for post hoc analysis of significance. Hemodynamic and echocardiographic differences between sham and CHF rabbits were determined with Student t test. Differences before and after intracerebroventricular infusion treatment in each group were analyzed with a paired t test. A P value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Effects of Intracerebroventricular Infusion of Ang II
In sham and CHF rabbits, intracerebroventricular infusion of Ang II (50 pM per 5 µL/min in artificial cerebrospinal fluid [aCSF]x30 minutes) significantly increased MAP (
12.4±3.1 mm Hg in sham, P<0.05;
25.5±3.7 mm Hg in CHF, P<0.01), and at the same time, lowered the RSNA (85.4±9.7% of control in sham, P<0.01; 74.9±6.1% of control in CHF, P<0.01) starting at
10 minutes, reaching a peak effect in
15 minutes, and then maintaining that level until the end of infusion. However, when the MAP was prevented from raising by intravenous infusion of sodium nitroprusside (25 µg/kg per minute) during intracerebroventricular infusion of Ang II, the RSNA was significantly increased (131.5±13.3% of control in sham, P<0.001; 193.6±11.9% of control in CHF, P<0.001), which was significantly greater in CHF than in sham rabbits (P<0.05; Figures 1 and 2
). In contrast, intracerebroventricular administration of aCSF caused no change in MAP or RSNA (data not shown).
|
|
Effects of Intracerebroventricular Losartan on Basal and Ang II-Induced RSNA
In CHF but not in sham rabbits, intracerebroventricular infusion of losartan significantly decreased basal RSNA (38.5±4.9% of control; P<0.05). However, in sham and CHF rabbits, when losartan was infused intracerebroventricularly 30 minutes before infusion of Ang II, the effect of Ang II on RSNA was completely abolished (Figure 3). Although there was a tendency for central administration of losartan to lower MAP (sham 76.1±6.3 to 72.8±4.6 mm Hg; CHF 67.9±4.4 to 60.7±6.1 mm Hg) and raise HR (sham 201.6±15.7 to 206.9±14.8 bpm; CHF 240.1±21.7 to 245.4±19.3 bpm), these changes did not reach statistical significance.
|
Effects of Intracerebroventricular Tempol, Apocynin, and DETC on Basal and Ang II-Induced RSNA
In CHF rabbits, intracerebroventricular infusion of tempol or apocynin significantly decreased the basal RSNA (49.7±8.9% of control for tempol, P<0.01; 39.6±9.6% of control for apocynin, P<0.01.), and in sham rabbits, although the RSNA tended to be lowered during intracerebroventricular treatment of tempol or apocynin, the differences did not reach statistical significance. However, pretreatment with intracerebroventricular infusion of tempol or apocynin blocked the effect of Ang II on RSNA in the two groups. On the other hand, in sham and CHF rabbits, intracerebroventricular infusion of the SOD inhibitor DETC (8 µg per 5 µL/min in aCSFx30 minutes) significantly increased the RSNA (219.7±12.2% of control in sham, P<0.001; 155.8±12.8% of control in CHF, P<0.001). The increase in sham rabbits was significantly greater than in CHF rabbits (P<0.05; Figure 4).
|
Expression of AT1 Receptor in RVLM
As shown in Figure 5, mRNA and protein expression of AT1 receptor in the RVLM were significantly upregulated in CHF rabbits compared with sham rabbits (mRNA 2.15±0.31 versus 0.66±0.22; protein 0.85±0.08 versus 0.38±0.09 arbitrary units, respectively).
|
Expression of NAD(P)H Subunits of RVLM
As is shown in Figure 6, mRNA and protein expression for p40phox, p47phox, and gp91phox were significantly increased in CHF rabbits compared with sham rabbits. There were no differences in mRNA or protein expression for p67phox in RVLM of sham and CHF rabbits. Because rabbit p67phox is 16 to 17 amino acids longer than any other (human, bovine, murine, and dolphin) known p67phox homolog,20 it migrated as a band of 73 kDa. In addition, we failed to detect mRNA expression for p22phox in RVLM of either sham or CHF rabbits. However, as a positive control, we observed mRNA expression of p22phox in liver and kidney of sham and CHF rabbit (data not shown).
|
Measurements of O2 Production in RVLM
NADPH-dependent superoxide production was significantly increased in the RLVM homogenates from CHF rabbits compared with that from sham rabbits (1.59±0.03 versus 0.53±0.01; P<0.05). The enhanced superoxide production in CHF rabbits was markedly inhibited by SOD, Tiron, apocynin, or phenylarsine oxide but was unaltered by oxypurinol, rotenone, or NG-nitro-L-arginine methyl ester (Figure 7).
|
In Situ Detection of O2 Production in RVLM
To provide in situ evidence that the O2 levels in the RVLM in CHF rabbits, confocal analysis of DHE fluorescence was used to estimate O2 levels in brain sections of sham and CHF rabbits. As shown in Figure 8, DHE fluorescence was increased in the RVLM of CHF rabbits (B and D) compared with sham rabbits (A and C).
|
| Discussion |
|---|
|
|
|---|
Growing evidence indicates that ROS are key mediators of Ang II signaling and that several important physiological functions of Ang II are directly mediated by ROS, including growth of vascular smooth muscle, induction of a vascular inflammatory responses, impairment of endothelium-dependent relaxation, and cardiac hypertrophy.25 On the other hand, there is extensive experimental evidence from in vitro and animal experiments that CHF is a state of oxidative stress.26 Moreover, recent data from animal studies8 as well as from patients27 support the role of increased oxidative stress in pathogenesis of CHF. On the basis of these findings, we hypothesized that ROS mediates the renal sympathoexcitatory effects of central Ang II. In the present study, we found that pretreatment with intracerebroventricular tempol or apocynin abolished the increased RSNA induced by intracerebroventricular Ang II in sham and CHF rabbits (Figure 4). These results indicate that NAD(P)H oxidase-derived ROS play an important role during Ang II-induced sympathoexcitation because the SOD mimetic tempol and the inhibitor of NAD(P)H oxidase apocynin were effective in blunting the response. Because tempol and apocynin significantly decreased basal RSNA in CHF, it is difficult to determine whether the lowered RSNA in the Ang II+tempol or Ang II+apocynin groups compared with the group given Ang II alone was attributable to either the basal effects of tempol and apocynin or to the blocking effect of these agents. However, in sham rabbits, although tempol and apocynin have no effects on basal RSNA, the RSNA in Ang II+tempol or Ang II+apocynin groups were lower than that in the Ang II group, indicating that tempol and apocynin blocked the sympathoexcitation induced by Ang II (Figure 4). Recently, Xu et al28 performed studies in anesthetized deoxycorticosterone acetate-salt hypertensive rats and found that tempol lowered blood pressure and sympathetic nerve activity but not vascular O2, indicating a direct sympathoinhibitory effect of this SOD mimetic. However, in two sham rabbits of the present study, we did not find that tempol potentiated the inhibitory effects of apocynin on the sympathoexcitatory response to intracerebroventricular Ang II (data not shown) when combining administration of tempol with apocynin.
The third major finding of the present study was that intracerebroventricular infusion of tempol or apocynin significantly decreased the basal RSNA in conscious CHF rabbits (Figure 4), indicating that enhanced oxidative stress promotes a tonic sympathoexcitatory effect in the CHF state. In contrast, in sham rabbits, we failed to observe any change in RSNA during intracerebroventricular infusion of tempol or apocynin, indicating that in the normal state, the lower level of oxidative stress is not a necessary factor for maintaining baseline sympathetic outflow. In addition, we found that intracerebroventricular infusion of DETC, an SOD inhibitor that increases superoxide production,29 significantly increased RSNA in sham and CHF rabbits, and the extent of this increase was significantly greater in sham rabbits compared with CHF rabbits (Figure 4). This result suggests that central ROS directly excites sympathetic nerve activity, and that central SOD activity may be lower in CHF than that in the normal state. Recently, Shokoji et al30 performed studies in anesthetized normotensive and hypertensive rats and found that intravenous administration of DETC rapidly increased RSNA in both groups of rats. However, the authors did not evaluate the central or peripheral action of DETC in these experiments.
It is well known that the RVLM plays a critical role in the generation and maintenance of sympathetic nerve activity.31 Recent studies showed that the RVLM contains high concentrations of AT1 receptors32 and is a major site of the sympathoexcitatory action of central Ang II.12 In the present study, we measured the expression of AT1 receptors in the RVLM by RT-PCR and Western Blot analysis and confirmed the upregulation of AT1 receptors in RVLM of CHF rabbits (Figure 5). In a previous study from this laboratory, we confirmed a significant increase in the cerebrospinal fluid concentration of Ang II in dogs with pacing-induced heart failure.33 These results imply that in the heart failure state, elevated central Ang II may act to upregulate AT1 receptors in the RVLM. This, in turn, may increase sympathetic outflow via stimulation of NAD(P)H oxidase-derived ROS. Recently, Yoshimura et al34 and Tan et al35 demonstrated that in the subfornical organ, the paraventricular hypothalamic nuclei, and the solitary tract nuclei of rats with heart failure, AT1 receptor expression was markedly upregulated and AT1 receptor binding density was significantly increased.
NAD(P)H oxidase is a multicomponent enzyme complex that consists of the two membrane-spanning polypeptide subunits p22phox and gp91phox (which, together, comprise flavocytochrome b558), and three cytoplasmic polypeptide subunits p40phox, p47phox, and p67phox to produce superoxide.36 NAD(P)H oxidase was first found and has been best characterized in phagocytic cells.37 However, recent studies showed that NAD(P)H oxidase proteins also have been localized in neurons.38 In this study, we provided evidence for the existence of mRNA and protein expression of all of the NAD(P)H oxidase subunits except for p22phox in the RVLM of sham and CHF rabbits (Figure 6), implying NAD(P)H oxidase-derived ROS may play a role in the central regulation of sympathetic outflow. As noted above, a variety of studies have documented that Ang II upregulates the gene expression of most NAD(P)H oxidase subunits.6,7 At the same time, Ang II concentration is significantly increased in the cerebrospinal fluid of CHF dogs, 33 and the AT1 receptor mRNA and protein expression in the RVLM is significantly upregulated in CHF rabbits (Figure 5). In the current study, we found that CHF rabbits exhibited a significant enhancement of p40phox, p47phox, and gp91phox subunits in the RVLM compared with sham rabbits. This observation correlated positively with changes in NADPH-dependent O2 production (Figures 7 and 8
), supporting the view of a functional upregulation of these components in RVLM of the CHF state. These increases would be expected to contribute to higher NAD(P)H oxidase O2-generating activity because increases in individual components have been shown to enhance NAD(P)H oxidase activity in cell-free assays.36 The above results imply that in the CHF state, an enhanced central Ang II mechanism(s) stimulates NAD(P)H oxidase subunit gene expression in the RVLM to increase O2 formation.
In summary, we show that intracerebroventricular Ang II significantly increased RSNA in sham and CHF rabbits. These responses were abolished by intracerebroventricular losartan, tempol, and apocynin. Intracerebroventricular tempol and apocynin significantly reduced resting RSNA in CHF but not in sham rabbits. Intracerebroventricular DETC significantly increased the RSNA in CHF and sham rabbits. The mRNA and protein expression of AT1 receptor and the NAD(P)H oxidase subunits p40phox, p47phox, and gp91phox in the RVLM were significantly upregulated in CHF rabbits compared with sham rabbits. NADPH-dependent superoxide anion was increased in the RVLM in CHF rabbits. These data demonstrate intense radical stress in an important autonomic area of the brain in experimental CHF and provide evidence for a tight relationship between Ang II and ROS as contributors to the sympathoexcitation in CHF.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87: VI40VI48.[Medline] [Order article via Infotrieve]
3. Kinugawa T, Ogino K, Kitamura H, Saitoh M, Omodani H, Osaki S, Hisatome I, Miyakoda H. Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at rest and during submaximal exercise in patients with congestive heart failure. Am J Med Sci. 1996; 312: 110117.[CrossRef][Medline] [Order article via Infotrieve]
4. Reid IA. Interactions between Ang II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992; 262: E763E778.[Medline] [Order article via Infotrieve]
5. Hanna IR, Taniyama Y, Szocs K, Rocic P, Griendling KK. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal. 2002; 4: 899914.[CrossRef][Medline] [Order article via Infotrieve]
6. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002; 22: 18451851.
7. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002; 90: E58E65.[CrossRef][Medline] [Order article via Infotrieve]
8. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation. 1997; 96: 24142420.
9. Khaper N, Singal PK. Effects of afterload-reducing drugs on pathogenesis of antioxidant changes and congestive heart failure in rats. J Am Coll Cardiol. 1997; 29: 856861.[Abstract]
10. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res. 2004; 94: 402409.
11. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail. 2002; 8: 132140.[Medline] [Order article via Infotrieve]
12. Head GA, Saigusa T, Mayorov DN. Angiotensin and baroreflex control of the circulation. Braz J Med Biol Res. 2002; 35: 10471059.[Medline] [Order article via Infotrieve]
13. Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH. Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol. 2001; 280: R1906R1913.
14. Liu JL, Zucker IH. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res. 1999; 84: 417423.
15. Li JM, Shah AM. Differential N. Cardiovasc Res. 2001; 52: 477486.
16. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003; 278: 1209412100.
17. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem. 2002; 277: 1995219960.
18. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004; 95: 210216.
19. Palkovits M, Brownstein M. Brain microdissection techniques. In: Brain Microdissection Techniques. Cuello AE, ed. Chichester, UK: Wiley; 1983.
20. Gauss KA, Mascolo PL, Siemsen DW, Nelson LK, Bunger PL, Pagano PJ, Quinn MT. Cloning and sequencing of rabbit leukocyte NADPH oxidase genes reveals a unique p67(phox) homolog. J Leukoc Biol. 2002; 71: 319328.
21. Liu JL, Murakami H, Sanderford M, Bishop VS, Zucker IH. Ang II and baroreflex function in rabbits with CHF and lesions of the area postrema. Am J Physiol. 1999; 277: H342H350.[Medline] [Order article via Infotrieve]
22. DiBona GF, Jones SY, Brooks VL. Ang II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am J Physiol. 1995; 269: R1189R1196.[Medline] [Order article via Infotrieve]
23. Jin XJ, Kannan H, Hayashida Y, Nakamura T, Higashino H, Yamashita H. Inhibition of renal sympathetic nerve activity of anesthetized rats by intracerebroventricular administration of angiotensin II. J UOEH. 1989; 11: 361370.[Medline] [Order article via Infotrieve]
24. Lazartigues E, Dunlay SM, Loihl AK, Sinnayah P, Lang JA, Espelund JJ, Sigmund CD, Davisson RL. Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice. Circ Res. 2002; 90: 617624.
25. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept. 2000; 91: 2127.[CrossRef][Medline] [Order article via Infotrieve]
26. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest. 2001; 120: 20352046.
27. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998; 31: 13521356.
28. Xu H, Fink GD, Galligan JJ. Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2 in DOCA-salt rats. Hypertension. 2004; 43: 329334.
29. Makino A, Skelton MM, Zou AP, Roman RJ, Cowley AW Jr. Increased renal medullary oxidative stress produces hypertension. Hypertension. 2002; 39: 667672.
30. Shokoji T, Nishiyama A, Fujisawa Y, Hitomi H, Kiyomoto H, Takahashi N, Kimura S, Kohno M, Abe Y. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension. 2003; 41: 266273.
31. Granata AR, Ruggiero DA, Park DH, Joh TH, Reis DJ. Lesions of epinephrine neurons in the rostral ventrolateral medulla abolish the vasodepressor components of baroreflex and cardiopulmonary reflex. Hypertension. 1983; 5: V80V84.[Medline] [Order article via Infotrieve]
32. Head GA. Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin Exp Pharmacol Physiol Suppl. 1996; 3: S93S98.[Medline] [Order article via Infotrieve]
33. Wang W, Ma R. Cardiac sympathetic afferent reflexes in heart failure. Heart Fail Rev. 2002; 5: 5771.
34. Yoshimura R, Sato T, Kawada T, Shishido T, Inagaki M, Miyano H, Nakahara T, Miyashita H, Takaki H, Tatewaki T, Yanagiya Y, Sugimachi M, Sunagawa K. Increased brain angiotensin receptor in rats with chronic high-output heart failure. J Card Fail. 2000; 6: 6672.[Medline] [Order article via Infotrieve]
35. Tan J, Wang H, Leenen FH. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol. 2004; 286: H1665H1671.
36. DeLeo FR, Quinn MT. Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leukoc Biol. 1996; 60: 677691.[Abstract]
37. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys. 2002; 397: 342344.[CrossRef][Medline] [Order article via Infotrieve]
38. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S. Activation of NADPH oxidase in Alzheimers disease brains. Biochem Biophys Res Commun. 2000; 273: 59.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
H. Zheng, Y.-F. Li, W. Wang, and K. P. Patel Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1364 - R1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker, H. D. Schultz, K. P. Patel, W. Wang, and L. Gao Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1557 - H1566. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H.H. Chan, C.-A. Wu, K. L.H. Wu, Y.-H. Ho, A. Y.W. Chang, and J. Y.H. Chan Transcriptional Upregulation of Mitochondrial Uncoupling Protein 2 Protects Against Oxidative Stress-Associated Neurogenic Hypertension Circ. Res., October 23, 2009; 105(9): 886 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Floras Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 375 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Israel, J. Arzola, S. De Jesus, and M. Varela Role of oxidative stress in the natriuresis induced by central administration of angiotensin II Journal of Renin-Angiotensin-Aldosterone System, March 1, 2009; 10(1): 9 - 14. [Abstract] [PDF] |
||||
![]() |
Y. Ding, Y.-L. Li, M. C. Zimmerman, R. L. Davisson, and H. D. Schultz Role of CuZn superoxide dismutase on carotid body function in heart failure rabbits Cardiovasc Res, March 1, 2009; 81(4): 678 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Torres Carotid body and sympathetic activation in heart failure: a story of sensors and sensitivity Cardiovasc Res, March 1, 2009; 81(4): 633 - 634. [Full Text] [PDF] |
||||
![]() |
A. Nagae, M. Fujita, H. Kawarazaki, H. Matsui, K. Ando, and T. Fujita Sympathoexcitation by Oxidative Stress in the Brain Mediates Arterial Pressure Elevation in Obesity-Induced Hypertension Circulation, February 24, 2009; 119(7): 978 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H.H. Chan, K. L.H. Wu, A. Y.W. Chang, M.-H. Tai, and J. Y.H. Chan Oxidative Impairment of Mitochondrial Electron Transport Chain Complexes in Rostral Ventrolateral Medulla Contributes to Neurogenic Hypertension Hypertension, February 1, 2009; 53(2): 217 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Lindley, D. W. Infanger, M. Rishniw, Y. Zhou, M. F. Doobay, R. V. Sharma, and R. L. Davisson Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R1 - R8. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao, W.-Z. Wang, W. Wang, and I. H. Zucker Imbalance of Angiotensin Type 1 Receptor and Angiotensin II Type 2 Receptor in the Rostral Ventrolateral Medulla: Potential Mechanism for Sympathetic Overactivity in Heart Failure Hypertension, October 1, 2008; 52(4): 708 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Wang, L. Gao, H.-J. Wang, I. H. Zucker, and W. Wang Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT1 receptors in heart failure Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1216 - H1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. W. Cheng, T. Murohara, M. Kuzuya, H. Izawa, T. Sasaki, K. Obata, K. Nagata, T. Nishizawa, M. Kobayashi, T. Yamada, et al. Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment Am. J. Pathol., August 1, 2008; 173(2): 358 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu, L. Gao, S. K. Roy, K. G. Cornish, and I. H. Zucker Role of Oxidant Stress on AT1 Receptor Expression in Neurons of Rabbits With Heart Failure and in Cultured Neurons Circ. Res., July 18, 2008; 103(2): 186 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Mousa, D. Liu, K. G. Cornish, and I. H. Zucker Exercise training enhances baroreflex sensitivity by an angiotensin II-dependent mechanism in chronic heart failure J Appl Physiol, March 1, 2008; 104(3): 616 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vecoli and N. Paolocci When the heart sleeps... Is the vagus resetting the myocardial 'redox clock'? Cardiovasc Res, March 1, 2008; 77(4): 609 - 611. [Full Text] [PDF] |
||||
![]() |
Y. Yu, S.-G. Wei, Z.-H. Zhang, E. Gomez-Sanchez, R. M. Weiss, and R. B. Felder Does Aldosterone Upregulate the Brain Renin-Angiotensin System in Rats With Heart Failure? Hypertension, March 1, 2008; 51(3): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-H. Zhang, Y. Yu, Y.-M. Kang, S.-G. Wei, and R. B. Felder Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1067 - H1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Han, Z. Shi, F. Zhang, Y. Yu, M.-K. Zhong, X.-Y. Gao, W. Wang, and G.-Q. Zhu Reactive oxygen species in the paraventricular nucleus mediate the cardiac sympathetic afferent reflex in chronic heart failure rats Eur J Heart Fail, October 1, 2007; 9(10): 967 - 973. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yu, Z.-H. Zhang, S.-G. Wei, Y. Chu, R. M. Weiss, D. D. Heistad, and R. B. Felder Central Gene Transfer of Interleukin-10 Reduces Hypothalamic Inflammation and Evidence of Heart Failure in Rats After Myocardial Infarction Circ. Res., August 3, 2007; 101(3): 304 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Li, L. Gao, I. H. Zucker, and H. D. Schultz NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits Cardiovasc Res, August 1, 2007; 75(3): 546 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nozoe, Y. Hirooka, Y. Koga, Y. Sagara, T. Kishi, J. F. Engelhardt, and K. Sunagawa Inhibition of Rac1-Derived Reactive Oxygen Species in Nucleus Tractus Solitarius Decreases Blood Pressure and Heart Rate in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, July 1, 2007; 50(1): 62 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Belardinelli Exercise Training in Chronic Heart Failure: How to Harmonize Oxidative Stress, Sympathetic Outflow, and Angiotensin II Circulation, June 19, 2007; 115(24): 3042 - 3044. [Full Text] [PDF] |
||||
![]() |
L. Gao, W. Wang, D. Liu, and I. H. Zucker Exercise Training Normalizes Sympathetic Outflow by Central Antioxidant Mechanisms in Rabbits With Pacing-Induced Chronic Heart Failure Circulation, June 19, 2007; 115(24): 3095 - 3102. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Mayorov Brain superoxide as a key regulator of the cardiovascular response to emotional stress in rabbits Exp Physiol, May 1, 2007; 92(3): 471 - 479. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doerries, K. Grote, D. Hilfiker-Kleiner, M. Luchtefeld, A. Schaefer, S. M. Holland, S. Sorrentino, C. Manes, B. Schieffer, H. Drexler, et al. Critical Role of the NAD(P)H Oxidase Subunit p47phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction Circ. Res., March 30, 2007; 100(6): 894 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bedard and K.-H. Krause The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology Physiol Rev, January 1, 2007; 87(1): 245 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Liu, L. Gao, S. K. Roy, K. G. Cornish, and I. H. Zucker Neuronal Angiotensin II Type 1 Receptor Upregulation in Heart Failure: Activation of Activator Protein 1 and Jun N-Terminal Kinase Circ. Res., October 27, 2006; 99(9): 1004 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Zimmet and J. M. Hare Nitroso-Redox Interactions in the Cardiovascular System Circulation, October 3, 2006; 114(14): 1531 - 1544. [Full Text] [PDF] |
||||
![]() |
G. Wang, J. Anrather, M. J. Glass, M. J. Tarsitano, P. Zhou, K. A. Frys, V. M. Pickel, and C. Iadecola Nox2, Ca2+, and Protein Kinase C Play a Role in Angiotensin II-Induced Free Radical Production in Nucleus Tractus Solitarius Hypertension, September 1, 2006; 48(3): 482 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-L. Li, X.-H. Xia, H. Zheng, L. Gao, Y.-F. Li, D. Liu, K. P. Patel, W. Wang, and H. D. Schultz Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits Cardiovasc Res, July 1, 2006; 71(1): 129 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sakai, Y. Hirooka, H. Shigematsu, T. Kishi, K. Ito, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2159 - H2166. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker and L. Gao The Regulation of Sympathetic Nerve Activity by Angiotensin II Involves Reactive Oxygen Species and MAPK Circ. Res., October 14, 2005; 97(8): 737 - 739. [Full Text] [PDF] |
||||
![]() |
S. H.H. Chan, K.-S. Hsu, C.-C. Huang, L.-L. Wang, C.-C. Ou, and J. Y.H. Chan NADPH Oxidase-Derived Superoxide Anion Mediates Angiotensin II-Induced Pressor Effect via Activation of p38 Mitogen-Activated Protein Kinase in the Rostral Ventrolateral Medulla Circ. Res., October 14, 2005; 97(8): 772 - 780. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao, W. Wang, Y.-L. Li, H. D. Schultz, D. Liu, K. G. Cornish, and I. H. Zucker Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure: Roles of Angiotensin II Type 1 Receptors and NAD(P)H Oxidase Circulation, September 20, 2005; 112(12): 1763 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sun, K. W. Sellers, C. Sumners, and M. K. Raizada NAD(P)H Oxidase Inhibition Attenuates Neuronal Chronotropic Actions of Angiotensin II Circ. Res., April 1, 2005; 96(6): 659 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kimura, Y. Hirooka, Y. Sagara, K. Ito, T. Kishi, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of Inducible Nitric Oxide Synthase in Rostral Ventrolateral Medulla Causes Hypertension and Sympathoexcitation via an Increase in Oxidative Stress Circ. Res., February 4, 2005; 96(2): 252 - 260. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |